Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MB | P02144 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.35 |
| ▸ | PGR | P06401 | 3/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.32 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31180367 | 0.80 | HTR2A (0.37) | PDE3BPDE3ACYP11B1CYP11B2 | |
| SCHEMBL25190883 | 0.80 | CYP11B1 (0.34) | PDE3BPDE3APGRCYP11B1CYP11B2 | |
| SCHEMBL4613940 | 0.76 | CDK5 (0.40) | MBCYP11B1CYP11B2 | |
| SCHEMBL21493526 | 0.74 | MB (0.35) | MBCYP11B1CYP11B2 | |
| SCHEMBL3524460 | 0.74 | AHR (0.41) | PDE3BPDE3AKCNH2 | |
| SCHEMBL436138 | 0.72 | HTR5A (0.42) | MBCYP11B1CYP11B2MMP12 | |
| SCHEMBL17442893 | 0.72 | NPC1 (0.39) | PDE3BPDE3AMMP12 | |
| SCHEMBL286899 | 0.70 | KCNJ1 (0.60) | KCNJ1KCNH2 | |
| SCHEMBL30445186 | 0.70 | KCNJ1 (0.60) | KCNJ1KCNH2 | |
| SCHEMBL8197651 | 0.70 | MMP12 (0.45) | PDE3BPDE3APGRCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0830348-B1 | CYCLIC AMINE DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2002-09-04 | — | — | EP | disclosed |
| US-6268366-B1 | Amide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists | WARNER-LAMBERT COMPANY | 2001-07-31 | — | — | US | disclosed |
| US-6191134-B1 | STROKE THERAPY, ANTIISCHEMIC AGENTS, BRAIN DISORDERS | WARNER-LAMBERT COMPANY | 2001-02-20 | — | — | US | disclosed |
| US-6172065-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY | 2001-01-09 | — | — | US | disclosed |
| US-6110911-A | ADMINISTERING NEUROPROTECTANT/ANTICONVULSANT TO PATIENT | WARNER-LAMBERT COMPANY (US) | 2000-08-29 | — | — | US | disclosed |
| US-6096744-A | ANTICONVULSANTS | WARNER-LAMBERT COMPANY (US) | 2000-08-01 | — | — | US | disclosed |
| WO-1998023599-A1 | UREA AND THIOUREA DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |